P Reichardt

Summary

Affiliation: HELIOS Klinikum Wuppertal
Country: Germany

Publications

  1. ncbi request reprint Novel approaches to imatinib- and sunitinib-resistant GIST
    Peter Reichardt
    HELIOS Klinikum Bad Saarow, Department of Hematology, Oncology, and Palliative Care, Sarcoma Center Berlin Brandenburg, Pieskower Strasse 33, 15526 Bad Saarow, Germany
    Curr Oncol Rep 10:344-9. 2008
  2. ncbi request reprint Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate
    Eva Wardelmann
    Department of Pathology, University of Bonn Medical School, Bonn, Germany
    Clin Cancer Res 12:1743-9. 2006
  3. ncbi request reprint NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines
    George D Demetri
    J Natl Compr Canc Netw 5:S1-29; quiz S30. 2007
  4. doi request reprint Optimal use of targeted agents for advanced gastrointestinal stromal tumours
    Peter Reichardt
    HELIOS Klinikum Bad Saarow, Bad Saarow, Germany
    Oncology 78:130-40. 2010
  5. doi request reprint [Soft tissue sarcomas and gastrointestinal stromal tumors]
    P Reichardt
    Sarkomzentrum Berlin Brandenburg, Klinik für Interdisziplinäre Onkologie, Helios Klinikum Berlin Buch, Schwanebecker Chaussee 50, 13125, Berlin, Deutschland
    Internist (Berl) 57:245-56. 2016
  6. pmc Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial
    Peter Reichardt
    Department of Interdisciplinary Oncology, Helios Klinikum Berlin Buch, Schwanebecker Chaussee 50, 13125, Berlin, Germany
    BMC Cancer 16:22. 2016
  7. doi request reprint Soft tissue sarcomas, a look into the future: different treatments for different subtypes
    Peter Reichardt
    Helios Klinikum Berlin Buch, Department of Interdisciplinary Oncology, Schwanebecker Chaussee 50, 13125 Berlin, Germany
    Future Oncol 10:s19-27. 2014
  8. doi request reprint New fronts in the adjuvant treatment of GIST
    Peter Reichardt
    Department of Hematology, Oncology and Palliative Medicine, HELIOS Klinikum Bad Saarow, Pieskower Strasse 33, 15526, Bad Saarow, Germany
    Cancer Chemother Pharmacol 72:715-23. 2013
  9. doi request reprint Current questions in soft tissue sarcoma: further steps with Yondelis®
    Peter Reichardt
    Helios Klinikum Berlin Buch, Department of Interdisciplinary Oncology, Schwanebecker Chaussee 50, 13125 Berlin, Germany
    Expert Rev Anticancer Ther 13:25-30. 2013
  10. doi request reprint Adjuvant therapy in primary GIST: state-of-the-art
    P Reichardt
    Interdisciplinary Oncology, Helios Klinikum Berlin Buch, Berlin, Germany
    Ann Oncol 23:2776-81. 2012

Detail Information

Publications53

  1. ncbi request reprint Novel approaches to imatinib- and sunitinib-resistant GIST
    Peter Reichardt
    HELIOS Klinikum Bad Saarow, Department of Hematology, Oncology, and Palliative Care, Sarcoma Center Berlin Brandenburg, Pieskower Strasse 33, 15526 Bad Saarow, Germany
    Curr Oncol Rep 10:344-9. 2008
    ....
  2. ncbi request reprint Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate
    Eva Wardelmann
    Department of Pathology, University of Bonn Medical School, Bonn, Germany
    Clin Cancer Res 12:1743-9. 2006
    ..According to our results, the identification of newly acquired KIT mutations in addition to the primary mutation is dependent on the number of tissue samples analyzed and has high implications for further therapeutic strategies...
  3. ncbi request reprint NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines
    George D Demetri
    J Natl Compr Canc Netw 5:S1-29; quiz S30. 2007
    ....
  4. doi request reprint Optimal use of targeted agents for advanced gastrointestinal stromal tumours
    Peter Reichardt
    HELIOS Klinikum Bad Saarow, Bad Saarow, Germany
    Oncology 78:130-40. 2010
    ..Individualisation of therapy may help to maximise clinical benefit of therapy in these patients...
  5. doi request reprint [Soft tissue sarcomas and gastrointestinal stromal tumors]
    P Reichardt
    Sarkomzentrum Berlin Brandenburg, Klinik für Interdisziplinäre Onkologie, Helios Klinikum Berlin Buch, Schwanebecker Chaussee 50, 13125, Berlin, Deutschland
    Internist (Berl) 57:245-56. 2016
    ..In patients with a mutation in KIT exon 9, 800 mg/day is the recommended dose. In imatinib refractory or intolerant patients, sunitinib is recommended. Regorafenib has been approved for third-line therapy. ..
  6. pmc Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial
    Peter Reichardt
    Department of Interdisciplinary Oncology, Helios Klinikum Berlin Buch, Schwanebecker Chaussee 50, 13125, Berlin, Germany
    BMC Cancer 16:22. 2016
    ..This study aimed to correlate KIT and PDGFRA mutational status with clinical outcome metrics (progression-free survival [PFS], overall survival [OS], objective response rate [ORR]) in a larger international patient population...
  7. doi request reprint Soft tissue sarcomas, a look into the future: different treatments for different subtypes
    Peter Reichardt
    Helios Klinikum Berlin Buch, Department of Interdisciplinary Oncology, Schwanebecker Chaussee 50, 13125 Berlin, Germany
    Future Oncol 10:s19-27. 2014
    ..Although much remains to be learned about these rare malignancies, it is anticipated that small steps taken in recent years will lead to bigger leaps forward in future. ..
  8. doi request reprint New fronts in the adjuvant treatment of GIST
    Peter Reichardt
    Department of Hematology, Oncology and Palliative Medicine, HELIOS Klinikum Bad Saarow, Pieskower Strasse 33, 15526, Bad Saarow, Germany
    Cancer Chemother Pharmacol 72:715-23. 2013
    ....
  9. doi request reprint Current questions in soft tissue sarcoma: further steps with Yondelis®
    Peter Reichardt
    Helios Klinikum Berlin Buch, Department of Interdisciplinary Oncology, Schwanebecker Chaussee 50, 13125 Berlin, Germany
    Expert Rev Anticancer Ther 13:25-30. 2013
    ..Trabectedin has made possible new models of care, such as long-term treatment and rechallenge. Its use has also fueled important and necessary debate about the criteria currently used to evaluate tumor response...
  10. doi request reprint Adjuvant therapy in primary GIST: state-of-the-art
    P Reichardt
    Interdisciplinary Oncology, Helios Klinikum Berlin Buch, Berlin, Germany
    Ann Oncol 23:2776-81. 2012
    ..The objectives of this European Expert Panel meeting were to describe the optimal management and best practice for the systemic adjuvant treatment of patients with primary GISTs...
  11. doi request reprint Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib
    P Reichardt
    HELIOS Klinikum Bad Saarow, Sarkomzentrum Berlin Brandenburg, Bad Saarow, Germany
    Ann Oncol 23:1680-7. 2012
    ..This phase III open-label trial investigated the efficacy of nilotinib in patients with advanced gastrointestinal stromal tumors following prior imatinib and sunitinib failure...
  12. doi request reprint Gastrointestinal stromal tumors: evolving role of the multidisciplinary team approach in management
    Peter Reichardt
    HELIOS Klinikum Bad Saarow GmbH, Germany
    Expert Rev Anticancer Ther 12:1053-68. 2012
    ..The benefits of multidisciplinary disease management of patients include reducing recurrent disease, optimizing timing of surgery and organ preservation, prolonging survival for the patient and enhancing response to targeted therapies...
  13. pmc Towards global consensus in the treatment of gastrointestinal stromal tumor
    Peter Reichardt
    Department of Hematology, Oncology and Palliative Medicine, HELIOS Klinikum Bad Saarow, Pieskower Strasse 33, D 15526 Bad Saarow, Germany
    Expert Rev Anticancer Ther 10:221-32. 2010
    ..A summary of consensus across these guidelines based on clinical trial data is juxtaposed with expert opinion where gaps in data still remain...
  14. doi request reprint [Gastrointestinal stromal tumour (GIST): current standards in multimodal management]
    P Reichardt
    HELIOS Klinkum Bad Saarow, Hämatologie, Onkologie und Palliativmedizin, Pieskower Strasse 33, Bad Saarow, Germany
    Zentralbl Chir 136:359-63. 2011
    ..After exploitation of all registered therapy options the patients should be offered an experimental therapy within the framework of a clinical trial...
  15. ncbi request reprint Molecular targeted therapy of gastrointestinal stromal tumors
    Peter Reichardt
    HELIOS Klinikum Bad Saarow, Department of Hematology, Oncology and Palliative Care, Sarcoma Center Berlin Brandenburg, Pieskower Strasse 33, 15526 Bad Saarow, Germany
    Curr Cancer Drug Targets 11:688-97. 2011
    ....
  16. doi request reprint [Internal medical therapy of gastrointestinal stroma tumors]
    P Reichardt
    Klinik fur Innere Medizin III, Sarkomzentrum Berlin Brandenburg, HELIOS Klinikum Bad Saarow, Pieskower Strasse 33, Bad Saarow, Germany
    Radiologe 49:1128-31. 2009
    ..Locally advanced GIST should be treated with systemic therapy prior to surgical resection. Imatinib was recently licensed for adjuvant therapy following complete surgical removal of GIST in patients with a significant risk of recurrence...
  17. doi request reprint [Systemic therapy of soft tissue sarcomas]
    D Pink
    Klinik für Innere Medizin III mit Schwerpunkt Hämatologie, Onkologie und Palliativmedizin, Sarkomzentrum Berlin Brandenburg, HELIOS Klinikum Bad Saarow, Pieskower Str 33, 15526 Bad Saarow, Deutschland
    Pathologe 32:65-71. 2011
    ..The first and highly successful targeted therapy was seen with the introduction of imatinib in the treatment of gastrointestinal stromal tumors...
  18. ncbi request reprint Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: Final results of a randomized trial (SSGXVIII/AIO)
    H Joensuu
    Helsinki University Central Hospital, Helsinki, Finland Lund University Hospital, Lund, Sweden Universitatsklinikum Schleswig Holstein, Kiel, Germany Oslo University Hospital, Oslo, Norway Marien Hospital Duesseldorf, Duesseldorf, Germany HELIOS Klinikum Berlin Buch, Sarcoma Center Berlin Brandenburg, Berlin, Germany University Hospitals Grosshadern, Ludwig Maximilians University, Munich, Germany University of Bonn, Bonn, Germany University of Goettingen, Goettingen, Germany Krankenhaus Nordwest, Frankfurt, Germany Sahlgrenska University Hospital, Gothenburg, Sweden Haukeland University Hospital, Oslo, Norway Oulu University Hospital, Oulu, Finland Helsinki University Hospital, Helsinki, Finland 4Pharma, Turku, Finland Universitätsklinikum Mannheim, Mannheim, Germany Lund University, Lund, Sweden HELIOS Klinikum Bad Saarow, Sarcoma Center Berlin Brandenburg, Bad Saarow, Germany
    J Clin Oncol 29:LBA1. 2011
    ..We compared 12 vs 36 mos of adjuvant IM as treatment of pts with a high risk for GIST recurrence after surgery...
  19. ncbi request reprint Nilotinib in advanced GIST: A retrospective analysis of nilotinib in compassionate use
    M Montemurro
    University Hospital, Lausanne, Switzerland Leuven Cancer Institute, Leuven, Belgium Helios Hospital, Bad Saarow, Germany Leiden University Medical Center, Leiden, The Netherlands Helsinki University Hospital, Helsinki, Finland Marien Hospital, Dusseldorf, Germany University Hospital, Koln, Germany South West German Comprehensive Cancer Center, Tubingen, Germany
    J Clin Oncol 26:10523. 2008
    ..Nilotinib is a second-generation TKI with at least similar inhibitory activity as imatinib, but reaching 7-10 fold higher intracellular concentrations. A Phase I study has shown that nilotinib monotherapy has clinical activity in GIST...
  20. doi request reprint Comparison of RECIST and Choi criteria for computed tomographic response evaluation in patients with advanced gastrointestinal stromal tumor treated with sunitinib
    O Dudeck
    Department of Radiology, HELIOS Clinic Berlin Buch, Berlin, Germany
    Ann Oncol 22:1828-33. 2011
    ..Controversies exist about computed tomography (CT) response evaluation criteria for patients with gastrointestinal stromal tumor (GIST)...
  21. ncbi request reprint Surgery in patients with metastatic or recurrent gastrointestinal stromal tumor (GIST) upon best response or limited progression following imatinib therapy
    U Ronellenfitsch
    University Hospital Mannheim, University of Heidelberg, Mannheim, Germany National Tumor Institute, Milan, Italy University Hospital Bonn, Bonn, Germany HELIOS Hospital, Bad Saarow, Germany
    J Clin Oncol 26:10555. 2008
    ..This study assesses long-term outcome for patients resected either upon clinical response or focal progression...
  22. ncbi request reprint Neoadjuvant imatinib and organ preservation in locally advanced gastrointestinal stromal tumors (GIST)
    P Hohenberger
    University of Heidelberg, Mannheim, Germany Schlossbergklinik, Oberstaufen, Germany German Cancer Research Center, Heidelberg, Germany HELIOS Klinikum Berlin, Berlin, Germany HELIOS Klinikum Bad Saarow, Berlin, Germany Department of Pathology, Medical School, University of Bonn, Bonn, Germany
    J Clin Oncol 27:10550. 2009
    ..10550 Background: We assessed the outcome of patients with locally advanced gastrointestinal stromal tumors (GIST) undergoing preoperative therapy with imatinib...
  23. doi request reprint Pattern of recurrence in patients with ruptured primary gastrointestinal stromal tumour
    P Hohenberger
    Division of Surgical Oncology and Thoracic Surgery, Oncology and Palliative Care, Helios Medical Centre, Bad Saarow, Germany
    Br J Surg 97:1854-9. 2010
    ..This study assessed the outcomes of patients with a gastrointestinal stromal tumour (GIST) that ruptured before or during resection...
  24. ncbi request reprint Sorafenib fourth-line treatment in imatinib-, sunitinib-, and nilotinib-resistant metastatic GIST: A retrospective analysis
    P Reichardt
    HELIOS Klinikum Bad Saarow, Sarcoma Center, Bad Saarow, Germany Vaud University Hospital, Oncology, Lausanne, Switzerland Leiden University Medical Center, Clinical Oncology, Leiden, Netherlands University Claude Bernard, Oncology, Lyon, France Sklodowska Curie Memorial Cancer Center, Warsaw, Poland Institut Bergonie, Oncology, Bordeaux, France South West German Comprehensive Cancer Center, Tubingen, Germany Marien Hospital, Interdisciplinary Oncology Center, Dusseldorf, Germany
    J Clin Oncol 27:10564. 2009
    ..Recently, clinical activity of sorafenib in third-line treatment in patients with GIST after IM and SU failure has been shown (Wiebe et al. ASCO 2008, #10502)...
  25. ncbi request reprint Incidence of bone metastases in GIST: A single center analysis of 307 patients with metastatic disease
    M Schuler
    Helios Klinikum Berlin Buch, Berlin, Germany HELIOS Klinikum Bad Saarow, Bad Saarow, Germany Charité Campus Buch, Berlin, Germany
    J Clin Oncol 26:10565. 2008
    ..The most frequent metastatic sites are liver (65%) and peritoneum (21%). Lymph node (6%), bone (6%) and lung metastases (2%) are uncommon...
  26. ncbi request reprint Gastrointestinal stromal tumor of the rectum and rectovaginal space: A retrospective review
    C Mussi
    Istituto Nazionale Tumori, Milano, Italy University Hospital of Mannheim, Mannheim, Germany University Hospital of Bonn, Bonn, Germany Sarcoma center Berlin Brandenburg, Bad Saarow, Germany University Hospital Mannheim, Mannheim, Germany
    J Clin Oncol 26:10560. 2008
    ..10560 Background: The aim of the study was to assess the outcome of patients with gastrointestinal stromal tumors (GISTs) of the rectum and rectovaginal space...
  27. ncbi request reprint Docetaxel and capecitabine for advanced gastric cancer: Phase II study investigating dose dependent efficacy in two patient cohorts
    P C Thuss-Patience
    Charite, Campus Virchow Klinikum, Berlin, Germany HELIOS Kliniken Berlin Buch, Berlin, Germany Klinikum Ernst von Bergmann, Potsdam, Germany Praxis, Berlin, Germany HELIOS Klinikum Bad Saarow, Bad Saarow, Germany
    J Clin Oncol 26:4551. 2008
    ....
  28. ncbi request reprint Dose-intensive chemotherapy with ifosfamide, epirubicin, and filgrastim for adult patients with metastatic or locally advanced soft tissue sarcoma: a phase II study
    P Reichardt
    Department of Hematology, Oncology, and Tumorimmunology, Robert Rossle Klinik, Virchow Klinikum, Humboldt University, Berlin, Germany
    J Clin Oncol 16:1438-43. 1998
    ....
  29. doi request reprint The influence of tumor- and treatment-related factors on the development of local recurrence in osteosarcoma after adequate surgery. An analysis of 1355 patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols
    D Andreou
    Department of Orthopedic Oncology, Helios Klinikum Berlin Buch, Academic Teaching Hospital of the Charité Universitätsmedizin, Berlin
    Ann Oncol 22:1228-35. 2011
    ..Local recurrence (LR) in osteosarcoma is associated with very poor prognosis. We sought to evaluate which factors correlate with LR in patients who achieved complete surgical remission with adequate margins...
  30. ncbi request reprint Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: Final results of a randomized trial (SSGXVIII/AIO)
    H Joensuu
    Helsinki University Central Hospital, Helsinki, Finland Lund University Hospital, Lund, Sweden Universitatsklinikum Schleswig Holstein, Kiel, Germany Oslo University Hospital, Oslo, Norway Marien Hospital Duesseldorf, Duesseldorf, Germany HELIOS Klinikum Berlin Buch, Sarcoma Center Berlin Brandenburg, Berlin, Germany University Hospitals Grosshadern, Ludwig Maximilians University, Munich, Germany University of Bonn, Bonn, Germany University of Goettingen, Goettingen, Germany Krankenhaus Nordwest, Frankfurt, Germany Sahlgrenska University Hospital, Gothenburg, Sweden Haukeland University Hospital, Oslo, Norway Oulu University Hospital, Oulu, Finland Helsinki University Hospital, Helsinki, Finland 4Pharma, Turku, Finland Universitätsklinikum Mannheim, Mannheim, Germany Lund University, Lund, Sweden HELIOS Klinikum Bad Saarow, Sarcoma Center Berlin Brandenburg, Bad Saarow, Germany
    J Clin Oncol 29:LBA1. 2011
    ....
  31. ncbi request reprint Activity of paclitaxel in radiation induced and other secondary angiosarcomas
    D Pink
    HELIOS Klinikum Bad Saarow, Sarcoma Center, Bad Saarow, Germany
    J Clin Oncol 27:10578. 2009
    ..We report on a retrospectice single center experience with chemotherapy in 17 patients (pts.) with secondary angiosarcomas (SAS)...
  32. ncbi request reprint Effect of imatinib (IM) discontinuation after seven years of complete remission in a patient with metastatic GIST: A case report
    D Pink
    HELIOS Klinikum Bad Saarow, Sarcoma Center Berlin Brandenburg, Bad Saarow, Germany HELIOS Klinikum Berlin Buch, Sarcoma Center Berlin Brandenburg, Berlin, Germany
    J Clin Oncol 29:e20534. 2011
    ..However, due to individual reasons, pts in long-term complete remission sometimes (CR) raise the question, if their IM can be discontinuated safely...
  33. ncbi request reprint Irinotecan versus best supportive care (BSC) as second-line therapy in gastric cancer: A randomized phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
    P C Thuss-Patience
    Charite Universitatsmedizin Berlin, Campus Virchow Klinikum, Berlin, Germany HELIOS Klinikum Berlin Buch, Berlin, Germany Kreisklinik Aschersleben Staβfurt, Aschersleben, Germany WiSP Research Institute, Langenfeld, Germany HELIOS Klinikum Bad Saarow, Bad Saarow, Germany
    J Clin Oncol 27:4540. 2009
    ..Irinotecan has proven activity in 1st-line therapy. In this randomized phase III study we compared irinotecan to BSC to evaluate the value of 2nd- line chemotherapy for gastric cancer...
  34. doi request reprint Perioperative chemotherapy with docetaxel, cisplatin and capecitabine (DCX) in gastro-oesophageal adenocarcinoma: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO){dagger}
    P C Thuss-Patience
    Department of Haematology, Oncology and Tumorimmunology, Campus Virchow Klinikum, Charite University Medicine Berlin, Berlin, Germany
    Ann Oncol 23:2827-34. 2012
    ..This prospective multicentre phase II trial assessed the feasibility and efficacy of perioperative chemotherapy with docetaxel, cisplatin and capecitabine (DCX) in patients with gastro-oesophageal adenocarcinoma...
  35. ncbi request reprint The treatment of uterine sarcomas
    P Reichardt
    Department of Interdisciplinary Oncology, Sarcoma Center Berlin Brandenburg, Helios Klinikum Berlin Buch, Berlin, Germany
    Ann Oncol 23:x151-7. 2012
    ..Endometrial stromal sarcomas are usually hormonal receptor positive, which allows endocrine therapy in most cases...
  36. ncbi request reprint Influence of PET/CT on therapeutic management after resection of high-risk or very high-risk GIST
    J Bertz-Lepel
    HELIOS Klinikum Bad Saarow, Sarcoma Center Berlin Brandenburg, Bad Saarow, Germany HELIOS Klinikum Berlin Buch, Sarcoma Center Berlin Brandenburg, Berlin, Germany
    J Clin Oncol 29:e20516. 2011
    ..This study was performed to analyse the influence of PET/CT on further therapy management after resection of GIST...
  37. ncbi request reprint A European treatment protocol for bone sarcoma in patients older than 40 years
    S Ferrari
    Istitito Ortopedico Rizzoli, Bologna, Italy Norwegian Radium Hospital, Oslo, Norway Olgahospital Pädiatrisches Zentrum der Landeshau, Stuttgart, Germany Ospedale Gradenigo, Torino, Italy Istituto Nazionale Tumori, Milano, Italy Istituto Ortopedico Rizzoli, Bologna, Italy Lund University Hospital, Lund, Sweden Institut für MedizinischeOnkologie und Hämatologie, Zurich, Switzerland Charitè Virchow Klinikum, Berlin, Germany HELIOS Klinikum Bad Saarow, Berlin, Germany
    J Clin Oncol 27:10516. 2009
    ..10516 Background: EUROpean Bone Over 40 Sarcoma Study (EURO-B.O.S.S.) is the first prospective multicenter international study for patients 41 - 65 years old with high-grade bone sarcoma...
  38. ncbi request reprint Exatecan in pretreated adult patients with advanced soft tissue sarcoma: results of a phase II--study of the EORTC Soft Tissue and Bone Sarcoma Group
    P Reichardt
    Medizinische Klinik m S Hämatologie, Onkologie und Tumorimmunologie, Robert Rossle Klinik, Helios Klinikum Berlin Buch, Charite Campus Buch, Lindenberger Weg 80, 13125 Berlin, Germany
    Eur J Cancer 43:1017-22. 2007
    ..In pretreated soft tissue sarcoma patients, Exatecan is well tolerated but does not achieve any objective responses. However, with respect to progression-free survival, Exatecan did show some activity in leiomyosarcomas...
  39. ncbi request reprint Effect of FNCLCC grade 2 versus grade 3 on survival after neoadjuvant chemotherapy (NAC) plus or minus regional hyperthermia (RHT) in soft tissue sarcomas (STS): An analysis of the EORTC-ESHO Intergroup phase III study
    R D Issels
    Universitaet München, Grosshadern, Munich, Germany Institute for Medical Informatics, Biometry and Epidemiology, University of Munich, Munich, Germany University Hospital Medical Center, Medizinische Klinik III, Munich, Germany Erasmus University Medical Center, Rotterdam, Netherlands HELIOS Klinikum Bad Saarow, Sarcoma Center Berlin Brandenburg, Bad Saarow, Germany Haukeland University Hospital, Bergen, Norway Rigshospitalet, Copenhagen, Denmark Ludwig Maximilian University, Institute of Pathology, Munich, Germany Duke University Medical Center, Durham, NC University Hospital Duesseldorf, Duesseldorf, Germany University of Cologne, Medical Clinic I, Cologne, Germany Department of Surgery, Munich University Medical Center, Munich, Germany University Hospital Medical Center, Munich, Germany Medical University of Vienna, University Clinic of Orthopaedic Surgery, Vienna, Austria University Hospital Munich Grosshadern, Munich, Germany Centre Léon Bérard, Lyon
    J Clin Oncol 29:10021. 2011
    ..Overall survival (OS) was improved in pts who completed the induction therapy with RHT (Lancet Oncol 2010)...
  40. ncbi request reprint Doxorubicin (Doxo) and dacarbacin (DTIC) as first-line therapy for patients (pts) with locally advanced or metastatic leiomyosarcoma (LMS) and liposarcoma (LPS)
    U Bitz
    HELIOS Klinikum Bad Saarow, Sarcoma Center Berlin Brandenburg, Bad Saarow, Germany Internal Medicine C Haematology and Oncology, Transplant Centre, Ernst Moritz Arndt University, Greifswald, Germany
    J Clin Oncol 29:10094. 2011
    ..Monotherapy with doxo is still considered standard treatment in mSTS. Combination therapy results in higher response rates but did not yet demonstrate a benefit in overall survival in first-line treatment...
  41. ncbi request reprint Detailed analysis of survival and safety with sunitinib (SU) in a worldwide treatment-use trial of patients with advanced GIST
    P Reichardt
    HELIOS Klinikum Bad Saarow, Bad Saarow, Germany Asan Medical Center, Seoul, Republic of Korea Maria Sklodowska Curie Memorial Cancer Center, Warsaw, Poland University College Hospital NHS Trust, London, United Kingdom Pfizer Inc, New York, NY Dana Farber Cancer Institute, Boston, MA
    J Clin Oncol 26:10548. 2008
    ..The objectives of this study are to grant access to SU to GIST pts who are otherwise unable to obtain SU, and to obtain broad safety and efficacy data from a large GIST population...
  42. pmc Prognostic relevance of the mitotic count and the amount of viable tumour after neoadjuvant chemotherapy for primary, localised, high-grade soft tissue sarcoma
    D Andreou
    1 Department of General Orthopedics and Tumor Orthopedics, Munster University Hospital, Albert Schweitzer Campus 1, 48149 Munster, Germany 2 Department of Orthopedic Oncology, Sarcoma Center Berlin Brandenburg, Helios Klinikum Berlin Buch, Schwanebecker Chaussee 50, 13125 Berlin, Germany
    Br J Cancer 112:455-60. 2015
    ..We sought to examine whether mitotic count (MC) and the amount of viable tumour (VT) following neoadjuvant systemic chemotherapy (SC) for primary, localised, high-grade soft tissue sarcoma (STS) correlate with prognosis...
  43. ncbi request reprint Infectious complications after high-dose chemotherapy and autologous stem cell transplantation: comparison between patients with lymphoma or multiple myeloma and patients with solid tumors
    G Reich
    , Campus Berlin-Buch, , Department of Hematology, Oncology and Tumor Immunology, Humboldt University of Berlin, Germany
    Bone Marrow Transplant 27:525-9. 2001
    ..6% of patients with documented infections. With respect to the incidence, type and clinical course of infection, no significant differences between patients with lymphoma or multiple myeloma and those with solid tumors were detected...
  44. ncbi request reprint Chemotherapy in alveolar soft part sarcomas. What do we know?
    P Reichardt
    Medizinische Klinik m S Hämatologie, Onkologie und Tumorimmunologie, Robert Rossle Klinik, HELIOS Klinikum Berlin, Universitatsklinikum Charite, Humboldt Universitat zu Berlin, Berlin, Germany
    Eur J Cancer 39:1511-6. 2003
    ..ASPS patients should not be treated with chemotherapy outside of controlled clinical trials. New targets for specific biologically-directed therapies need to be developed...
  45. doi request reprint Gastrointestinal stromal tumors I: pathology, pathobiology, primary therapy, and surgical issues
    Peter Reichardt
    Sarcoma Center Berlin Brandenburg, HELIOS Klinikum Bad Saarow, Bad Saarow, Germany
    Semin Oncol 36:290-301. 2009
    ..The biological features of GIST make it a model for the examination of kinase-targeted therapeutics in solid tumors...
  46. ncbi request reprint Severe hypoglycemia caused by paraneoplastic production of IGF-II in patients with advanced gastrointestinal stromal tumors: a report of two cases
    Daniel Pink
    J Clin Oncol 23:6809-11. 2005
  47. ncbi request reprint Follow-up of gastro-intestinal stromal tumours (GIST) during treatment with imatinib mesylate by abdominal MRI
    Christian Stroszczynski
    Klinik und Poliklinik für Strahlenheilkunde, Campus Virchow Klinikum, Charite Universitatsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Germany
    Eur Radiol 15:2448-56. 2005
    ..01), when compared with non-responders. Beyond the size measurement for response assessment, MRI provides additional information of tumour response using SI of T2-w images and quantification of vascularised areas of GIST manifestations...
  48. ncbi request reprint Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg
    John R Zalcberg
    Department of Medical Oncology, Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Locked Bag 1, A Beckett Street, Melbourne, VIC 8006, Australia
    Eur J Cancer 41:1751-7. 2005
    ..1% of patients were still alive and progression free one year after cross-over. We conclude that a cross-over to high-dose imatinib is feasible and safe in GIST patients who progress on low-dose therapy...
  49. ncbi request reprint Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Gr
    Martine van Glabbeke
    EORTC Data Center, Av E Mounier, 83, Bte 8, B1200, Brussels, Belgium
    Eur J Cancer 42:2277-85. 2006
    ..A multivariate risk calculator that can be used in the clinic for individual patients is proposed...
  50. ncbi request reprint Imatinib and altered bone and mineral metabolism
    Heikki Joensuu
    N Engl J Med 355:628; author reply 628-9. 2006
  51. ncbi request reprint Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial
    Jaap Verweij
    Department of Medical Oncology, Erasmus University Medical Centre, Groene Hilledijk 301, 3075 EA Rotterdam, Netherlands
    Lancet 364:1127-34. 2004
    ..Imatinib is approved worldwide for use in gastrointestinal stromal tumours (GIST). We aimed to assess dose dependency of response and progression-free survival with imatinib for metastatic GIST...
  52. ncbi request reprint Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma
    Pierre Fumoleau
    Cancer 98:1325-6; author reply 1326-7. 2003
  53. doi request reprint Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up
    P G Casali
    Department of Cancer Medicine, Istituto Nazionale dei Tumori, Milan, Italy
    Ann Oncol 19:ii35-8. 2008